


Scientists develop novel therapy for Crimean-Congo hemorrhagic fever virus

2 June 2021



Credit: CC0 Public Domain

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected. Their results are published online today in the journal *Cell*.

Using [blood samples](#) donated by disease survivors, the study's authors characterized the human immune response to natural CCHFV infection. They were able to identify several potent neutralizing antibodies that target the viral glycoprotein—a component of the virus that plays a key role in disease development. Several of these antibodies, administered individually or in combination, protected mice from CCHFV when given prior to virus exposure.

To treat mice that had already been infected, the team created "bispecific" antibodies that combined potency with the ability to bind to two separate sites on the CCHFV glycoprotein. One of these bispecific antibodies, called DVD-121-801, overcame CCHFV infection in mice with just a

single dose administered 24 hours after challenge with live virus.

Efforts are underway to develop DVD-121-801 as a potential therapeutic for [human patients](#), according to co-first author Andrew H. Herbert, Ph.D., of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

CCHFV is the most prevalent tick-borne [virus](#) that causes human disease, and is endemic in countries across Europe, Asia, and Africa. Despite its high lethality and widespread distribution, no vaccines or specific treatments are available. It has been designated a priority pathogen by the World Health Organization.

"Rodent models of CCHFV infection are useful in testing and down-selecting neutralizing antibodies," commented Herbert. "However, to advance a lead candidate for therapeutic use, it will be necessary to conduct studies in larger animal models that more faithfully recapitulate human [disease](#)."

More information: J. Maximilian Fels et al, Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever, *Cell* (2021). [DOI: 10.1016/j.cell.2021.05.001](https://doi.org/10.1016/j.cell.2021.05.001)

Provided by US Army Medical Research Institute of Infectious Diseases

APA citation: Scientists develop novel therapy for Crimean-Congo hemorrhagic fever virus (2021, June 2) retrieved 4 September 2022 from <https://medicalxpress.com/news/2021-06-scientists-therapy-crimean-congo-hemorrhagic-fever.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.